Trial intelligence / Profile preview

Clindamycin/tretinoin gel versus Acnatac versus vehicle in papulopustular acne

2023-504552-10-01Phase 3Authorised

Sponsor
Dermapharm
Start
May 2024
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in acne papulopustulosa and acne vulgaris comparing Test clindamycin/tretinoin gel, Reference Acnatac gel and Vehicle control (3 arms). Primary endpoints: Percent change in inflammatory lesion count from baseline to week 12 and Percent change in total lesion count from baseline to week 12. Planned start May 2024; status: authorised.

02

Drugs

tretinoinclindamycin
03

Conditions

acne papulopustulosaacne vulgaris

Beyond the preview

Go deeper on 2023-504552-10-01.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-504552-10-01.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call